Novel inflammatory biomarkers in coronary artery disease: Potential therapeutic approaches

Current Medicinal Chemistry

Volumn 22, Issue 22, 2015, Pages 2680-2689

  Voudris, Konstantinos V ^a   Chanin, Jake ^a   Feldman, Dmitriy N ^a   Charitakis, Konstantinos ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndrome; Biomarkers; Coronary artery disease; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; HOMOCYSTEINE; ISCHEMIA MODIFIED ALBUMIN; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SERUM AMYLOID A; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTISENSE THERAPY; ARTICLE; CORONARY ARTERY DISEASE; HUMAN; INNATE IMMUNITY; INTRAVASCULAR ULTRASOUND; MEDLINE; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE ACTIVATION; BLOOD; INFLAMMATION;

BIOMARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; SERUM ALBUMIN; SERUM AMYLOID A PROTEIN;

EID: 84940863057     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150420124427     Document Type: Article

References (86)

1. Karmen, A.; Wroblewski, F.; LaDue, J. A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum. J. Clin. Invest., 1955, 34(1), 126-133.
2. Morrow DA. Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications. Cardiovasc. Toxicol., 2001, 1(2), 105-110.
3. Morrow, D.A.; Braunwald, E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation, 2003, 108(3), 250-252.
4. Wong, G.C.; Morrow, D.A.; Murphy, S.; Kraimer, N.; Pai, R.; James, D.; Robertson, D.H.; Demopoulos, L.A.; DiBattiste, P.; Cannon, C.P.; Gibson, C.M. Elevations in troponin T and I are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation, 2002, 106(2), 202-207.
5. Du, C.T.W. Function of C-reactive protein. Ann. Med., 2000, 32(4), 274-278.
6. Inoue, T.; Kato, T.; Uchida, T.; Sakuma, M.; Nakajima, A.; Shibazaki, M.; Imoto, Y.; Saito, M.; Hashimoto, S.; Hikichi, Y.; Node, K. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J. Am. Coll. Cardiol., 2005, 46(2), 239-245.
7. Ishikawa, T.; Hatakeyama, K.; Imamura, T.; Date, H.; Shibata, Y.; Hikichi, Y.; Asada, Y.; Eto, T. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am. J. Cardiol., 2003, 91(3), 287-292.
8. Calabro P.; Willerson JT.; Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 2003, 108(16), 1930-1932.
9. Yasojima K.; Schwab C.; McGeer EG.; McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol., 2001, 158(3), 1039-1051.
10. Jabs, W.J.; Theissing, E.; Nitschke, M.; Bechtel, J.F.; Duchrow, M.; Mohamed, S.; Jahrbeck, B.; Sievers, H.H.; Steinhoff J.; Bartels C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation, 2003, 108(12), 1428-1431.
11. Danenberg, H.D.; Szalai, A.J.; Swaminathan, R.V.; Peng, L.; Chen, Z.; Seifert, P.; Fay, W.P.; Simon, D.I.; Edelman, ER. Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice. Circulation, 2003, 108(5), 512-515.
12. Paul, A.; Ko, K.W.S.; Li, L.; Yechoor, V.; McCrory, M.A.; Szalai, A.J.; Chan, L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004, 109(5), 647-655.
13. Heeschen, C.; Hamm, C.W.; Bruemmer, J.; Simoons, M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J. Am. Coll. Cardiol., 2000, 35(6), 1535-1542.
14. Blake, G.J.; Ridker, P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am, Coll, Cardiol., 2003, 41(4 Suppl S), 37S-42S.
15. Gerszten, R.E.; Wang, T.J. The search for new cardiovascular biomarkers. Nature, 2008, 451(7181), 949-952.
16. Koenig, W.; Breitling, L.P.; Hahmann, H.; Wusten, B.; Brenner, H.; Rothenbacher, D. Cardiac troponin T measured by a highsensitivity assay predicts recurrent cardiovascular events in stable coronary heart disease patients with 8-year follow-up. Clin. Chem., 2012, 58(8), 1215-1224.
17. James, S.K.; Armstrong, P.; Barnathan, E.; Califf, R.; Lindahl, B.; Siegbahn, A.; Simoons, M.L.; Topol, E.J.; Venge, P.; Wallentin, L.; GUSTO-IV-ACS Investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: A GUSTO-IV substudy. J. Am, Coll, Cardiol., 2003, 41(6), 916-924.
18. Zamani, P.; Schwartz, G.G.; Olsson, A.G.; Rifai, N.; Bao, W.; Libby, P.; Ganz, P.; Kinlay, S. for the Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J. Am. Heart Assoc., 2013, 2(1), e003103.
19. Makrygiannis, S.S.; Ampartzidou, O.S.; Zairis, M.N.; Patsourakos, N.G.; Pitsavos, C.; Tousoulis, D.; Prekates, A.A.; Foussas, S.G.; Cokkinos, D.V. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction. Am. J. Cardiol., 2013, 111(1), 26-30.
20. Mueller, C.; Buettner, H.J.; Hodgson, J.M.; Marsch, S.; Perruchoud, A.P.; Roskamm, H.; Neumann, F.J. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation, 2002, 105(12), 1412-1415.
21. Cheng, J.M.; Oemrawsingh, R.M.; Garcia-Garcia, H.M.; Akkerhuis, K.M.; Kardys, I.; de Boer, S.P.; Langstraat, J.S.; Regar, E.; van Geuns, R.J.; Serruys, P.W.; Boersma, E. Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in Patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study). Am. J. Cardiol., 2014, 114(10), 1497-1503.
22. Wensley, F.; Gao, P.; Burgess, S.; Kaptoge, S.; Di, A. E.; Shah, T.; Engert, J.C.; Clarke, R.; Davey-Smith, G.; Nordestgaard, B.G.; Saleheen, D.; Samani, N.J.; Sandhu, M.; Anand, S.; Pepys, M.B.; Smeeth, L.; Whittaker, J.; Casas, J.P.; Thompson, S.G.; Hingorani, A.D.; Danesh, J. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ, 2011, 342, d548.
23. Pepys, M.B.; Hawkins, P.N.; Kahan, M.C.; Tennent, G.A.; Gallimore, J.R.; Graham, D.; Sabin, C.A.; Zychlinsky, A.; de Diego, J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res., 2005, 97(11), e97-103.
24. Lane, T.; Wassef, N.; Poole, S.; Mistry, Y.; Lachmann, H.J.; Gillmore, J.D.; Hawkins, P.N.; Pepys, M.B. Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ. Res., 2014, 114(4), 672-676.
25. Balk, E.M.; Lau, J.; Goudas, L.C.; Jordan, H.S.; Kupelnick, B.; Kim, L.U.; Karas, R.H. Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann. Intern. Med., 2003, 139(8), 670-682.
26. Wierzbicki, A.S.; Poston, R.; Ferro, A. The lipid and non-lipid effects of statins. Pharmacol. Ther., 2003, 99(1), 95-112.
27. Torzewski, J. C-reactive protein and atherogenesis: new insights from established animal models. Am. J. Pathol., 2005, 167(4), 923- 925.
28. Ma, Y.; Li, L.; Geng, X.B.; Hong, Y.; Shang, X.M.; Tan, Z.; Song, Y.X.; Zhao, G.Y.; Zhao, B.Q.; Tian, M.R. Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction. Am. J. Ther., 2014, [Epub ahead of print].
29. Kaur, R.; Das, R.; Ahluwalia, J.; Kumar, R.M.; Talwar, K.K. Genetic polymorphisms, biochemical factors, and conventional risk factors in young and elderly north indian patients with acute myocardial infarction. Clin. Appl. Thromb. Hemost., 2014, [Epub ahead of print].
30. Akyurek, O.; Akbal, E.; Gunes, F. Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level. Arch. Med. Res., 2014, 45(6), 501-506.
31. Gokay, S.; Cicek, D.; Muderrisoglu, H. Hyperhomocysteinemia in a young woman presenting with acute myocardial infarction: Case report. Interv. Med. Appl. Sci., 2013, 5(1), 39-42.
32. Ukachukwu, V.; Idris, S.; McIlwee, A. Acute myocardial infarction in a young patient with hyperhomocysteinaemia. BMJ Case Rep., 2012, pii: bcr2012007489.
33. Al-Obaidi, M.K.; Stubbs, P.J.; Collinson, P.; Conroy, R.; Graham, I.; Noble, M.I. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J. Am. Coll. Cardiol., 2000, 36(4), 1217-22.
34. Agoston-Coldea, L.; Mocan, T.; Seicean, A.; Gatfosse, M.; Rosenstingl, S. The plasma homocysteine concentrations and prior myocardial infarction. Rom. J. Intern. Med., 2010, 48(1), 65-72.
35. Kosuge, M.; Ebina, T.; Ishikawa, T.; Hibi, K.; Tsukahara, K.; Okuda, J.; Iwahashi, N.; Ozaki, H.; Yano, H.; Kusama, I.; Nakati, T.; Umemura, S.; Kimura, K. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ. J., 2007, 71(2), 186-190.
36. Katayama, T.; Nakashima, H.; Takagi, C.; Honda, Y.; Suzuki, S.; Iwasaki, Y.; Yano, K. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ. J., 2005, 69(10), 1186-1191.
37. Leroyer, A.S.; Rautou, P.E.; Silvestre, J.S.; Castier, Y.; Leseche, G.; Devue, C.; Duriez, M.; Brandes, R.P.; Lutgens, E.; Tedgui, A.; Boulanger, C.M. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J. Am. Coll. Cardiol., 2008, 52(16), 1302-1311.
38. Zhao, W.; Zhang, F.; Li, Z.; Yu, H.; Li, Z.; Gao, W. Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome. Chin. Med. J. (Engl), 2014, 127(12), 2218-2221.
39. Pusuroglu, H.; Akgul, O.; Erturk, M.; Uyarel, H.; Bulut, U.; Akkaya, E.; Buturak, A.; Surgit, O.; Fuat, A.; Cetin, M.; Yldrm, A. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron. Artery Dis., 2014, 25(7), 558-564.
40. Lindberg, S. Prognostic utility of the soluble CD40 ligand in acute coronary syndrome. Coron. Artery Dis., 2014, 25(7), 548-549.
41. Setianto, B.Y.; Hartopo, A.B.; Achadiono, D.N.; Gharini, P.P. Association between levels of circulating soluble CD40 ligand on admission and in-hospital events among acute coronary syndrome patients. Acta Med. Indones., 2011, 43(2), 82-87.
42. Morrow, D.A.; Sabatine, M.S.; Brennan, M.L.; de Lemos, J.A.; Murphy, S.A.; Ruff, C.T.; Rifai, N.; Cannon, C.P.; Hazen, S.L. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur. Heart J., 2008; 29(9), 1096-1102.
43. Jefferis, B.J.; Whincup, P.H.; Welsh, P.; Wannamethee, S.G.; Rumley, A.; Lawlor, D.A.; Ebrahim, S.; Lowe, G.D. Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case- control study of older men and women. J. Thromb. Haemost., 2011, 9(8), 1452-1459.
44. Vavuranakis, M.; Latsios, G.; Aggelis, D.; Bosinakou, I.; Karambelas, I.; Tousoulis, D.; Toutouzas, K.; Stefanadis, C. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin. Ther., 2006, 28(6), 860-871.
45. Furman, M.I.; Krueger, L.A.; Linden, M.D.; Fox, M.L.; Ball, S.P.; Barnard, M.R.; Frelinger, A.L. 3rd; Michelson, AD. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J. Thromb. Haemost., 2005, 3(2), 312-320.
46. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Avanzas, P.; Bosa-Ojeda, F.; Samimi-Fard, S.; Marrero-Rodriguez, F.; Kaski, J.C. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis, 2009, 206(2), 523-527.
47. Azar, R.R.; Kassab, R.; Zoghbi, A.; Aboujaoude, S.; El-Osta, H.; Ghorra, P.; Germanos, M.; Salame, E. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am. Heart J., 2006, 151(2), 521e1-521e4.
48. Ray, M.J.; Juneja, M.; Bett, N.; Walters, D.L. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention, 2009, 5(3), 330-335.
49. Murase, T.; Kume, N.; Kataoka, H.; Minami, M.; Sawamura, T.; Masaki, T.; Kita, T. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler. Thromb. Vasc. Biol., 2000, 20(3), 715-720.
50. Kume, N.; Mitsuoka, H.; Hayashida, K.; Tanaka, M.; Kominami, G.; Kita, T. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome- comparison with other biomarkers. J. Cardiol., 2010, 56(2), 159- 165.
51. Kobayashi, N.; Hata, N.; Kume, N.; Shinada, T.; Tomita, K.; Shirakabe, A.; Kitamura, M.; Nozaki, A.; Inami, T.; Seino, Y.; Mizuno, K. Soluble lectin-like oxidized LDL receptor-1 and highsensitivity troponin T as diagnostic biomarkers for acute coronary syndrome. Improved values with combination usage in emergency rooms. Circ. J., 2011, 75(12), 2862-2871.
52. Hayashida, K.; Kume, N.; Murase, T.; Minami, M.; Nakagawa, D.; Inada, T.; Tanaka, M.; Ueda, A.; Kominami, G.; Kambara, H.; Kimura, T.; Kita, T. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: A novel marker for early diagnosis. Circulation, 2005, 112(6), 812-818.
53. Kobayashi, N.; Takano, M.; Hata, N.; Kume, N.; Yamamoto, M.; Yokoyama, S.; Shinada, T.; Tomita, K.; Shirakabe, A.; Otsuka, T.; Seino, Y.; Mizuno, K. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma: verification by optical coherence tomography. Int. J. Cardiol., 2013, 168(4), 3217-3223.
54. Christenson, R.H.; Duh, S.H.; Sanhai, W.R.; Wu, A.H.; Holtman, V.; Painter, P.; Branham, E.; Apple, F.S.; Murakami, M.; Morris, D.L. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: A multicenter study. Clin. Chem., 2001, 47(3), 464-470.
55. Gidenne, S.; Ceppa, F.; Fontan, E.; Perrier, F.; Burnat, P. Analytical performance of the albumin cobalt binding (ACB) test on the Cobas MIRA plus analyzer. Clin. Chem. Lab Med., 2004, 42(4), 455-461.
56. Sbarouni, E.; Georgiadou, P.; Kremastinos, D.T.; Voudris, V. Ischemia modified albumin: Is this marker of ischemia ready for prime time use? Hellenic. J. Cardiol., 2008, 49(4), 260-266.
57. Sbarouni, E.; Georgiadou, P.; Panagiotakos, D.; Alivizatos, P.A.; Voudris, V. Increased ischaemia modified albumin following coronary artery bypass grafting. Biomarkers, 2009, 14(1), 38-42.
58. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers, 2010, 15(8), 655-662.
59. Lee, Y.W.; Kim, H.J.; Cho, Y.H.; Shin, H.B.; Choi, T.Y.; Lee, Y.K. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin. Chim. Acta, 2007, 384(1-2), 24-27.
60. Liebetrau, C.; Nef, H.M.; Dorr, O.; Gaede, L.; Hoffmann, J.; Hahnel, A.; Rolf, A.; Troidl, C.; Lackner, K.J.; Keller, T.; Hamm, C.W.; Mollmann, H. Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction. Heart, 2014, 100(8), 652-657.
61. Sokhanvar, S.; Mellati, A.O.; Mousavinasab, S.N.; Taran, L.; Vahdani, B.; Golmmohamadi, Z. Ischemia-modified albumin (IMA) in differential diagnosis of transient myocardial ischemia from non ischemic chest pain. Bratisl. Lek. Listy., 2012, 113(10), 612-615.
62. Wudkowska, A.; Goch, J.; Goch, A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol. Pol., 2010, 68(4), 431-437.
63. Gaze, D.C.; Crompton, L.; Collinson, P.O. Sample stability of ischemia modified albumin (IMA) as assessed by the Albumin Cobalt Binding (ACB™) test. Clin. Chem., 2003, 49, A40.
64. Weber, M.; Hamm, C. Novel biomarkers-the long march from bench to bedside. Eur. Heart J., 2008, 29(9), 1079-1081.
65. Schaub, N.; Reichlin, T.; Meune, C.; Twerenbold, R.; Haaf, P.; Hochholzer, W.; Niederhauser, N.; Bosshard, P.; Stelzig, C.; Freese, M.; Reiter, M.; Gea, J.; Buser, A.; Mebazaa, A.; Osswald, S.; Mueller, C. Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin. Chem., 2012, 58(1), 246-256.
66. Hazen, S.L. Myeloperoxidase and plaque vulnerability. Arterioscler. Thromb. Vasc. Biol., 2004, 24(7), 1143-1146.
67. Brennan, M.L.; Penn, MS.; Van Lente, F.; Nambi, V.; Shishehbor, M.H.; Aviles, R.J.; Goormastic, M.; Pepoy, M.L.; McErlean, E.S.; Topol, E.J.; Nissen, S.E.; Hazen, S.L. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med., 2003, 349(17), 1595-1604.
68. Baldus, S.; Heeschen, C.; Meinertz, T.; Zeiher, A.M.; Eiserich, J.P.; Munzel, T.; Simoons, M.L.; Hamm, CW.; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003, 108(12), 1440- 1445.
69. Peacock, W.F.; Nagurney, J.; Birkhahn, R.; Singer, A.; Shapiro, N.; Hollander, J.; Glynn, T.; Nowak, R.; Safdar, B.; Miller, C.; Peberdy, M.; Counselman, F.; Chandra, A.; Kosowsky, J.; Neuenschwander, J.; Schrock, J.; Plantholt, S.; Lewandrowski, E.; Wong, V.; Kupfer, K.; Diercks, D. Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum. Am. Heart J., 2011, 162(5), 893-899.
70. Koch, C.; Henrich, M.; Heidt, M.C. Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia. Clin. Cardiol., 2014, 37(12), 744-749.
71. Dullaart, R.P.; Tietge, U.J.; Kwakernaak, A.J.; Dikkeschei, B.D.; Perton, F.; Tio, R.A. Alterations in plasma lecithin:cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis, 2014, 234(1), 185-192.
72. Searle, J.; Shih, J.; Muller, R.; Vollert, J.O.; Muller, C.; Danne, O.; Datwyler, S.; Mockel, M. The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department. Eur. Heart J. Acute Cardiovasc. Care, 2013, 2(3), 203-210.
73. Bunn, R.C.; Fowlkes, J.L. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol. Metab., 2003, 14(4), 176- 181.
74. Sangiorgi, G.; Mauriello, A.; Bonanno, E.; Oxvig, C.; Conover, C.A.; Christiansen, M.; Trimarchi, S.; Rampoldi, V.; Holmes, D.R.; Schwartz, R.S.; Spagnoli, L.G. Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: A link between inflammation and cerebrovascular events. J. Am. Coll. Cardiol., 2006, 47(11), 2201-2211.
75. Lund, J.; Qin, Q.P.; Ilva, T.; Nikus, K.; Eskola, M.; Porela, P.; Kokkala, S.; Pulkki, K.; Pettersson, K.; Voipio-Pulkki, L.M. Pregnancy-associated plasma protein A: A biomarker in acute STelevation myocardial infarction (STEMI). Ann. Med., 2006, 38(3), 221-228.
76. Lund, J.; Qin, Q.P.; Ilva, T.; Pettersson, K.; Voipio-Pulkki, L.M.; Porela, P.; Pulkki, K. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation, 2003, 108(16), 1924-1926.
77. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94(6), 2493-2503.
78. Inokubo, Y.; Hanada, H.; Ishizaka, H.; Fukushi, T.; Kamada, T.; Okumura, K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J., 2001, 141(2), 211-217.
79. Kai, H.; Ikeda, H.; Yasukawa, H.; Kai, M.; Seki, Y.; Kuwahara, F.; Ueno, T.; Sugi, K.; Imaizumi, T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 1998, 32(2), 368-372.
80. Blankenberg, S.; Rupprecht, H.J.; Poirier, O.; Bickel, C.; Smieja, M.; Hafner, G.; Meyer, J.; Cambien, F.; Tiret, L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003, 107(12), 1579-1585.
81. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta, 2000, 1477(1-2), 267-283.
82. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ. Res., 2002, 90(3), 251-262.
83. Cavusoglu, E.; Ruwende, C.; Chopra, V.; Yanamadala, S.; Eng, C.; Clark, L.T.; Pinsky, D.J.; Marmur, J.D. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of allcause mortality, cardiac mortality, and myocardial infarction. Am. Heart J., 2006, 151(5), 1101e1-8.
84. Lubos, E.; Schnabel, R.; Rupprecht, H.J.; Bickel, C.; Messow, C.M.; Prigge, S.; Cambien, F.; Tiret, L.; Munzel, T.; Blankenberg, S. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: Results from the AtheroGene study. Eur. Heart J., 2006, 27(2), 150-156.
85. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92(8), 827-839.
86. Crea, F.; Liuzzo, G. Pathogenesis of acute coronary syndromes. J. Am. Coll. Cardiol., 2013, 61(1), 1-11.